Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
- PMID: 35085501
- DOI: 10.1016/S0140-6736(22)00105-2
Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
Conflict of interest statement
MAC declares no competing interests. PAK declares fees from DeepMind for consultancy in automated analysis of retinal imaging with deep learning, for Roche in personalised health care, for Novartis in personalised health care, for Apellis in automated analysis of geographic atrophy, and for BitFount in privacy protecting machine learning. PAK has received speaker fees from Heidelberg Engineering, Topcon, Allergan, and Bayer, outside the area of work commented on here. PAK declares equity ownership in Big Picture Medical, a telemedicine enterprise, unrelated to the topic commented on here.
Comment on
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical